A 753-share sale covers stock-vesting taxes at Relay Therapeutics (RLAY).
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
Peter Rahmer, Chief Corporate Development Officer at Relay Therapeutics (RLAY), sold 753 shares of common stock at Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context